Document is current
Any future updates will be listed below
-
Authors
Dy, Amanda
Buetow, Sandra M.
Bredemeyer, Andrew J.
Saini, Monika Lamba
Lucas, Fabienne
Bennett, Shannon
Blenman, Kim R. M.
Wharton, Keith Jr.
Singhal, Sunil
de Baca, M. E.
Schap, Kevin
Hanna, Matthew G.
Kearney, Staci J.
Zerbe, Norman
Salgado, Roberto
Veetil, Jithesh
Seheult, Jansen N.
McClintock, David S.
Khademi, April
Lennerz, Jochen K.
-
Funding
Funding for this research was provided by:
Natural Sciences and Engineering Research Council of Canada (NSERC) Vanier Canada Graduate Scholarship (198875)
Bundesministerium für Gesundheit (2523DAT400)
Canada Research Chairs Program
Canadian Cancer Society Emerging Scholar Award
Mitacs Accelerate
- License Information
-
More Information
Article History
Received: 31 July 2025
Accepted: 12 February 2026
First Online: 5 March 2026
Competing interests
: K.W.: employee and interest holder of Roche Diagnostics, former employee and interest holder in Danaher, Novartis, and Ultivue/Vizgen; MdB: employee of Sysmex America, Inc., Governor, College of American Pathologists; K.R.M.B.: received research funding from Carevive; R.S.: served as advisory board member for BMS, Roche, Astra Zeneca, Daichii Sankyo, Exact Sciences. R.S. is an unpaid advisor to Case45. R.S. has received research funding by Roche, Puma, Merck, BMS. R.S. is member of an advisory group to the Belgian Government on reimbursement of assays in genomics and pathology. R.S. is co-Chair of The International Immuno-Oncology Biomarker Working Group ( ). R.S. has no financial conflicts of interests related to the current work presented; J.K.L.: employee of BostonGene; All other author declared no relevant conflicts of interest.
